Akebia Therapeutics (AKBA) Income from Non-Controlling Interests (2019 - 2021)

Akebia Therapeutics (AKBA) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$3000.0 in Q2 2021.

• On a quarterly basis, Income from Non-Controlling Interests rose 66.67% year-over-year to -$3000.0 in Q2 2021; TTM through Mar 2022 was -$3000.0, a 133.33% decrease from a year earlier, with the FY2021 full-year figure at -$7000.0, down 153.85% from the prior year.
• Income from Non-Controlling Interests for Q2 2021 stood at -$3000.0, up from -$4000.0 in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for AKBA reached as high as $225000.0 in Q1 2019 and fell as low as -$17000.0 in Q3 2019.
• Historically, Income from Non-Controlling Interests has averaged $29666.7 across 3 years, with a median of -$3000.0 in 2021.
• On a YoY basis, Income from Non-Controlling Interests climbed as much as 216.67% in 2020 and fell as far as 115.25% in 2020.
• Year by year, Income from Non-Controlling Interests stood at -$6000.0 in 2019, then surged by 216.67% to $7000.0 in 2020, then sank by 142.86% to -$3000.0 in 2021.
• Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$3000.0 in Q2 2021, -$4000.0 in Q1 2021, and $7000.0 in Q4 2020.